Clinical trial
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or…
NCT02924376 · Incyte Corporation, Industry · Completed
Key facts
| NCT number | NCT02924376 |
|---|---|
| Title | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) |
| Official title | A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202) |
| Lead sponsor | Incyte Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cholangiocarcinoma |
| Intervention type | Drug |
| Interventions | Pemigatinib |
| Enrollment | 147 |
| Start date | Jan 16, 2017 |
| Primary completion | Feb 1, 2022 |
| Completion | Feb 1, 2022 |
| First posted | Oct 5, 2016 |
| Last update posted | Aug 14, 2025 |
| Countries | Belgium, France, Germany, Israel, Italy, Japan, South Korea, Spain, Taiwan, Thailand, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: